The following pages link to Tom Huizinga (Q77086497):
Displaying 50 items.
- Tumor necrosis factor-alpha +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease (Q24802526) (← links)
- Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis (Q24812184) (← links)
- Tweaking microtubules to treat scleroderma (Q25255541) (← links)
- Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis (Q26852235) (← links)
- Selective involvement of the amygdala in systemic lupus erythematosus (Q28212921) (← links)
- Rheumatoid arthritis: Seronegative and seropositive RA: alike but different? (Q28251716) (← links)
- Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci (Q28281906) (← links)
- Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis (Q28304210) (← links)
- Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis (Q28489093) (← links)
- Association between several clinical and radiological determinants with long-term clinical progression and good prognosis of lower limb osteoarthritis (Q28743565) (← links)
- Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci (Q28943258) (← links)
- Genetics of rheumatoid arthritis contributes to biology and drug discovery (Q29417000) (← links)
- A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases (Q30276804) (← links)
- Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases (Q30278872) (← links)
- High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis (Q30419111) (← links)
- Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry (Q30426245) (← links)
- Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause (Q30582352) (← links)
- Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial (Q30964201) (← links)
- New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis (Q30988023) (← links)
- A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis (Q33299576) (← links)
- Redefining the HLA and RA association: to be or not to be anti-CCP positive. (Q33341777) (← links)
- A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. (Q33354118) (← links)
- Tumor necrosis factor-alpha genetic predisposing factors can influence clinical severity in nephropathia epidemica (Q33372716) (← links)
- Autoimmune responses in the rheumatoid synovium. (Q33399866) (← links)
- The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. (Q33750031) (← links)
- Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody-negative arthralgia patients at risk for rheumatoid arthritis (Q33765720) (← links)
- A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis (Q33766411) (← links)
- Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge (Q33855802) (← links)
- Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis (Q33904381) (← links)
- TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies (Q33923265) (← links)
- Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis (Q34027510) (← links)
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial (Q34092311) (← links)
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (Q34110066) (← links)
- 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative (Q34130671) (← links)
- Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis (Q34216613) (← links)
- Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis (Q34374946) (← links)
- The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis (Q34461215) (← links)
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study (Q34465354) (← links)
- Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis (Q34535766) (← links)
- Genetics in rheumatoid arthritis (Q34637304) (← links)
- The battle between anti-cyclic citrullinated peptide and rheumatoid factor tests--a winner at last? (Q34710594) (← links)
- Profiling the secretion of soluble mediators by end stage osteoarthritis synovial tissue explants reveals a reduced responsiveness to an inflammatory trigger (Q34712675) (← links)
- Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis (Q34736545) (← links)
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report (Q34802740) (← links)
- Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period (Q34818608) (← links)
- Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus (Q34896821) (← links)
- Fc-glycosylation of IgG1 is modulated by B-cell stimuli (Q34994340) (← links)
- A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis (Q35053861) (← links)
- Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis (Q35062220) (← links)
- Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene (Q35092644) (← links)